Privacy-Preserving Identity Verification for Telecoms
P6/10June 12, 2026
WhatA zero-knowledge proof based identity verification layer that lets telcos comply with regulations without storing sensitive PII, using cryptographic attestations instead of raw personal data.
SignalThere is deep tension between regulators wanting accountability on phone networks and consumers who are terrified of yet another PII honeypot at breach-prone telcos — a technical middle ground that satisfies both sides has real demand.
Why NowThe FCC's proposed KYC rules for telecom are creating urgent regulatory pressure while ZK-proof infrastructure has finally matured enough for production use cases.
MarketTelcos and MVNOs paying for compliance infrastructure; TAM in the hundreds of millions across US carriers alone. Competitors like Prove and Telesign do identity but not privacy-preserving verification.
MoatDeep regulatory expertise combined with cryptographic IP creates high switching costs once embedded in carrier compliance workflows.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.